BioCentury | Jul 17, 2014
Distillery Techniques

Technology: Drug platforms

...stem immunogen that harbors about 95% of the epitope bound by the broadly neutralizing antibody CR6261...
...mice and ferrets. Johnson & Johnson's Crucell N.V. unit has the hemagglutinin-targeting, broadly neutralizing antibody CR6261...
BioCentury | Jan 30, 2014
Distillery Therapeutics

Indication: Infectious disease

...Crucell N.V. unit collaborated on this study and also has the HA-targeting, broadly neutralizing antibody CR6261...
BioCentury | Jul 11, 2013
Distillery Therapeutics

Indication: Infectious disease

...prevent influenza infection. Normal mice receiving intramuscular injection with an AAV vector encoding F10 or CR6261...
...were protected from challenge with at least three diverse strains of influenza virus. F10 and CR6261...
BioCentury | Mar 5, 2009
Distillery Therapeutics

Indication: Infectious disease

...conserved influenza HA epitope could prevent or treat seasonal or pandemic influenza infections. Cocrystals of CR6261...
BioCentury | Mar 5, 2009
Cover Story

Anti-flubodies

...and then screened those libraries against recombinant H5 hemagglutinin. The lead antibody from that screen, CR6261...
...In a follow-on study in Science, another Crucell-led team reported structural studies of an H5 hemagglutinin-CR6261...
...has an LAIV in Phase I testing to prevent pandemic flu. Goudsmit noted that Crucell's CR6261...
BioCentury | Jan 5, 2009
Clinical News

Crucell preclinical data

...In mice, CR6261 was 100% successful in preventing H5N1 infection compared with all mice suffering respiratory...
...compared with all mice suffering respiratory symptoms by day 4 with an isotype control mAb. CR6261...
...Gilead Sciences Inc. (NASDAQ:GILD, Foster City, Calif.). Crucell N.V. (Euronext:CRXL; NASDAQ:CRXL), Leiden, the Netherlands Product: CR6261...
Items per page:
1 - 6 of 6